Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

465.27
-0.8300-0.18%
Volume:43.88K
Turnover:20.45M
Market Cap:118.05B
PE:30.37
High:468.45
Open:468.40
Low:463.19
Close:466.10
52wk High:517.20
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.49
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:6.32
PE(LYR):30.37

Loading ...

Vertex Pharmaceuticals Q4 Adj. EPS $5.03 Misses $5.07 Estimate, Sales $3.190B Beat $3.176B Estimate

Benzinga
·
Feb 13

Vertex posts FY2025 GAAP operating income of USD 4.17 billion

Reuters
·
Feb 13

Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Revenue $3.19B, vs. FactSet Est of $3.18B

MT Newswires Live
·
Feb 13

BRIEF-Vertex Pharmaceuticals Q4 Adjusted EPS USD 5.03 Vs. IBES Estimate USD 5.07

Reuters
·
Feb 13

Vertex Pharmaceuticals Q4 Total REV $3.19 Bln VS Ibes Estimate $3.18 Bln

THOMSON REUTERS
·
Feb 13

Vertex Pharmaceuticals: Preparing for Anticipated Near‑Term Commercialization of Povetacicept in Igan

THOMSON REUTERS
·
Feb 13

Vertex Pharmaceuticals: Expects $500 Mln or More in REV From Non-CF Products in 2026

THOMSON REUTERS
·
Feb 13

Vertex Pharmaceuticals Q4 EPS USD 4.65

THOMSON REUTERS
·
Feb 13

U.S. Earnings Preview: After Market Close Feb. 12

Dow Jones
·
Feb 13

Vertex Shares Fall After Jefferies Downgrade

MT Newswires Live
·
Feb 13

Vertex Is Maintained at Neutral by Citigroup

Dow Jones
·
Feb 13

Morgan Stanley Cuts Price Target on Vertex to $20 From $33, Keeps Overweight Rating

MT Newswires Live
·
Feb 12

Vertex 9-Mos Net Y9.00B Vs Net Y3.01B

Dow Jones
·
Feb 12

Vertex downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Feb 12

Vertex Is Maintained at Buy by Needham

Dow Jones
·
Feb 12

Vertex price target lowered to $16 from $23 at Stifel

TIPRANKS
·
Feb 12

Vertex: Compressed Valuation, Scaling FCF, and SAP-Driven ARR Catalysts Support Buy Rating

TIPRANKS
·
Feb 12

Vertex Pharmaceuticals’ povetacicept granted FDA orphan designation

TIPRANKS
·
Feb 11

Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says

MT Newswires Live
·
Feb 11

RBC Capital Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 10